Bisphosphonates may reduce risk of certain breast, colon, and lung cancers
the ONA take:
According to two new studies published in the journal Proceedings of the National Academy of Sciences (PNAS), researchers at the Icahn School of Medicine at Mount Sinai in New York, New York, have found that bisposphonates, a commonly used class of drug to treat osteoporosis, may also prevent certain types of breast, colon, and lung cancers.
The first study analyzes how bisphosphonates block abnormal tumor growth through the human epidermal growth factor (HER) receptors, and the second study describes how bisphosphonates could be used in cancer prevention, in combination with existing treatments, and against treatment-resistant cancers. Certain types of breast, colon, and non-small cell lung cancers are driven by genetic mutations that cause the overexpression of HER family receptors.
The study found that bisphosphonates bind to kinase domains for HER proteins, thereby preventing pathway signaling that would ultimately cause cancer growth. This mechanism is similar to that of drugs that inhibit tyrosine kinases like trastuzumab and erlotinib; however, cancers often become resistant to these treatments after the tumor develops a second genetic mutation.
The findings suggest that bisphosphonates may continue to inhibit HER family receptors even after a second mutation is present, making these drugs a potential treatment for those cancers that become resistant to primary therapy.
Bisposphonates may also prevent certain types of breast, colon, and lung cancers.
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Rubraca Granted Accelerated FDA Approval for Advanced BRCA-positive Ovarian Cancer
- New Criteria for Appropriate Use of Bone Scintigraphy to Diagnose and Manage Prostate and Breast Cancer
- Primary Care Physicians Surveyed on Breast Cancer Screening Practices
- Low Acculturated Latina Women Reported Breast Cancer Treatment Experience Differently Than Other Groups
- Cost and Complication Rates Differ Among Early Breast Cancer Treatment Options
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|